Predictors of low‐level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort
Hortensia Álvarez(Complexo Hospitalario Universitario A Coruña), Josep M. Llibre(Badalona Serveis Assistencials), Antonio Rivero(University of Southern California), Joaquín Portilla(Hospital General Universitario de Alicante Doctor Balmis), Eva Poveda(Madrid Health Service), Marta Rava(Instituto de Salud Carlos III), Ana Mariño(Universitat Autònoma de Barcelona), Joaquim Peraire(Instituto de Salud Carlos III), Miguel Cervero(Hospital Universitario Severo Ochoa), Cristina Martínez(University Hospital Complex Of Vigo)
Cited by 14
Related Papers
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
|The Lancet Infectious Diseases|2015|143
Less Lipoatrophy and Better Lipid Profile With Abacavir as Compared to Stavudine
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2006|137
A Randomized Clinical Trial Comparing Nelfinavir Or Nevirapine Associated to Zidovudine/Lamivudine in HIV-Infected Naive Patients (The Combine Study)
|Antiviral Therapy|2002|137